Q1 2026 results

We delivered strong growth in Q1 2026, with Total Revenue above $15 billion, demonstrating our consistent commercial execution. We are advancing through our catalyst‑rich period, with positive readouts for four high-value Phase III programmes since our last quarterly results, including first pivotal data for two key new molecular entities (NMEs).

Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca